



Sosei Announces Collaboration with Toa Pharmaceuticals and Nitto Medic

Tokyo, Japan – 12 May 2011: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), announced today that it and its wholly owned subsidiary Activus Pharma (“Activus”) have entered into a Joint Development Agreement with Toa Pharmaceuticals Co., Ltd (“Toa”) and its subsidiary Nitto Medic Co., Ltd (“Nitto”).

Under the terms of the agreement, Toa and Nitto, both which has proven track-record and know-how in the manufacturing and sales of medical products, and Sosei and Activus will jointly conduct research and development to assess the feasibility of developing various ophthalmic solutions applying Activus Pure Nano-particle Technology (“APNT”).

Once a product has been identified for development, a separate agreement towards commercialization will be executed.

Enquiries:

Sosei Group Corporation	
Tokyo Office	London Office
Milica STOJKOVIC, Investor Relations	Kathryn LYDON, PA to CEO & Corporate Communication
+81-(0)3-5210-3399	+44-(0)20-7691-0983
mstojkovic@sosei.com	KLydon@sosei.com

Notes for Editors:

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets. For further information about Sosei, please visit www.sosei.com.

About Toa

<http://www.toyakuhin.co.jp/english/top.html>

About Nitto

<http://www.nittomedic.co.jp/english/top.html>

Forward-Looking Statements

This press release contains “forward-looking statements”, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.